Use of metformin and survival of diabetic women with breast cancer

Current Drug Safety

Volumn 8, Issue 5, 2013, Pages 357-363

  Peeters, Paul J H L ^a   Bazelier, Marloes T ^a   Vestergaard, Peter ^b   Leufkens, Hubert G M ^a   Schmidt, Marjanka K ^c   de Vries, Frank ^a,d,e,f   de Bruin, Marie L ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^f MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Breast cancer; Metformin; Mortality; Survival; Type 2 diabetes mellitus

Indexed keywords

BIGUANIDE; BUFORMIN; INSULIN; METFORMIN; PHENFORMIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER SURVIVAL; CAUSE OF DEATH; DIABETES MELLITUS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; PRESCRIPTION; PRIORITY JOURNAL; RISK REDUCTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; COHORT STUDIES; COMORBIDITY; DENMARK; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; MIDDLE AGED; REGISTRIES; RISK FACTORS; SURVIVAL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84891528073     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/15680266113136660069     Document Type: Article

References (26)

1. Renehan AG, Yeh HC, Johnson JA, Wild SH, Gale EA, Moller H. Diabetes and cancer (2): Evaluating the impact of diabetes on mortality in patients with cancer. Diabetologia 2012; 55(6): 1619-1632.
2. Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA, Morgan CL. Mortality after incident cancer in people with and without type 2 diabetes: Impact of metformin on survival. Diabetes Care 2012; 35(2): 299-304.
3. Peairs KS, Barone BB, Snyder CF, et al. Diabetes mellitus and breast cancer outcomes: A systematic review and meta-analysis. J Clin Oncol 2011; 29(1): 40-46.
4. Redaniel MT, Jeffreys M, May MT, Ben-Shlomo Y, Martin RM. Associations of type 2 diabetes and diabetes treatment with breast cancer risk and mortality: A population-based cohort study among british women. Cancer Causes Control 2012; 23(11): 1785-1795.
5. Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, Bilo HJ. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 2010; 33(2): 322-326.
6. Bowker SL, Yasui Y, Veugelers P, Johnson JA. Glucose-lowering agents and cancer mortality rates in type 2 diabetes: Assessing effects of time-varying exposure. Diabetologia 2010; 53(8): 1631-1637.
7. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006; 66(21): 10269-10273.
8. Alimova IN, Liu B, Fan Z, et al. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 2009; 8(6): 909-915.
9. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007; 67(22): 10804-10812.
10. Chappell J, Leitner JW, Solomon S, Golovchenko I, Goalstone ML, Draznin B. Effect of insulin on cell cycle progression in MCF-7 breast cancer cells. direct and potentiating influence. J Biol Chem 2001; 276(41): 38023-38028.
11. Zakikhani M, Blouin MJ, Piura E, Pollak MN. Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Res Treat 2010; 123(1): 271-279.
12. Bonanni B, Puntoni M, Cazzaniga M, et al. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol 2012; 30(21): 2593-2600.
13. Hadad S, Iwamoto T, Jordan L, et al. Evidence for biological effects of metformin in operable breast cancer: A pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res Treat 2011; 128(3): 783-794.
14. Niraula S, Dowling RJ, Ennis M. Metformin in early breast cancer: A prospective window of opportunity neoadjuvant study. Breast Cancer Res Treat 2012; 135(3): 821-830.
15. Jiralerspong S, Palla SL, Giordano SH, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009; 27(20): 3297-3302.
16. He X, Esteva FJ, Ensor J, Hortobagyi GN, Lee MH, Yeung SC. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. Ann Oncol 2011; 23(7): 1771-80.
17. Lega IC, Austin PC, Gruneir A, Goodwin PJ, Rochon PA, Lipscombe LL. Association between metformin therapy and mortality after breast cancer: A population-based study. Diabetes Care 2013; 36(10): 3018-26.
18. Mosbech J, Jorgensen J, Madsen M, Rostgaard K, Thornberg K, Poulsen TD. The national patient registry. evaluation of data quality. Ugeskr Laeger 1995; 157(26): 3741-3745.
19. Kildemoes HW, Sorensen HT, Hallas J. The danish national prescription registry. Scand J Public Health 2011; 39(7 Suppl): 38-41.
20. WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC classification and DDD assignment 2013. Oslo, 2012.
21. Pedersen CB. The danish civil registration system. Scand J Public Health 2011; 39(7 Suppl): 22-25.
22. Bazelier MT, Vestergaard P, Gallagher AM, et al. Risk of fracture with thiazolidinediones: Disease or drugs? Calcif Tissue Int 2012; 90(6): 450-457.
23. Osborne CK, Bolan G, Monaco ME, Lippman ME. Hormone responsive human breast cancer in long-term tissue culture: Effect of insulin. Proc Natl Acad Sci USA 1976; 73(12): 4536-4540.
24. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987; 40(5): 373-383.
25. Bayraktar S, Hernadez-Aya LF, Lei X, et al. Effect of metformin on survival outcomes in diabetic patients with triple receptornegative breast cancer. Cancer 2012; 118(5): 1202-1211.
26. Suissa S, Azoulay L. Metformin and the risk of cancer: Timerelated biases in observational studies. Diabetes Care 2012; 35(12): 2665-2673.